Stock Analysis on Net

Analysis of Short-term (Operating) Activity Ratios 
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Danaher Corp., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Turnover Ratios
Inventory turnover 3.90 4.04 3.67 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87
Receivables turnover 6.49 6.28 6.46 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87
Payables turnover 5.68 5.45 5.78 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04
Working capital turnover 3.83 4.13 7.39 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91
Average No. Days
Average inventory processing period 94 90 99 101 96 88 101 102 98 96 104 102 104 91 96 98 94
Add: Average receivable collection period 56 58 56 54 54 54 54 51 52 60 59 55 53 57 51 54 53
Operating cycle 150 148 155 155 150 142 155 153 150 156 163 157 157 148 147 152 147
Less: Average payables payment period 64 67 63 65 66 66 60 63 62 65 65 63 64 67 65 73 72
Cash conversion cycle 86 81 92 90 84 76 95 90 88 91 98 94 93 81 82 79 75

Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).


The analysis of short-term operating activity indicates a general stability in asset and liability management, characterized by cyclical fluctuations and a significant period of volatility in working capital efficiency between late 2023 and late 2024.

Inventory and Receivables Management
Inventory turnover remains relatively consistent, fluctuating between 3.50 and 4.15. A recurring pattern of improved efficiency is observed every December, with turnover peaking at 4.15 in December 2024 and 4.04 in December 2025. Consequently, the average inventory processing period shows a corresponding dip toward the end of the calendar year, reaching a minimum of 88 days in December 2024.
Receivables management demonstrates high stability. The receivables turnover ratio generally oscillates between 6.09 and 7.15, with the average collection period remaining tightly controlled between 51 and 60 days. This suggests a disciplined and predictable credit collection process across the entire observed period.
Payables and Working Capital Efficiency
Payables turnover is stable, ranging from 5.00 to 6.04. The average payables payment period has remained consistent, typically fluctuating between 60 and 67 days since 2022, indicating a steady relationship with suppliers and a consistent approach to managing short-term obligations.
Working capital turnover exhibits the highest degree of volatility. After a decline to a low of 2.18 on September 29, 2023, the ratio experienced a sharp increase, peaking at 8.85 by December 31, 2024. This substantial surge suggests a significant optimization of current assets or a reduction in net working capital relative to sales during this window, before returning to lower levels of 3.83 by March 2026.
Operating and Cash Conversion Cycles
The operating cycle shows moderate variation, peaking at 163 days in September 2023 and reaching a low of 142 days in December 2024. These movements are primarily driven by fluctuations in inventory processing times rather than receivable collection speeds.
The cash conversion cycle (CCC) follows a similar trajectory, with values ranging from 75 to 98 days. The CCC peaked in September 2023, coinciding with the peak in the operating cycle. A notable contraction occurred in December 2024, where the CCC dropped to 76 days, reflecting a period of enhanced liquidity and faster cash recovery from investments in inventory and receivables.

Overall, the operational activity is characterized by a reliable collection and payment cadence. While inventory and cycle durations fluctuate slightly on a seasonal basis, the most prominent trend is the temporary and significant spike in working capital turnover during 2024, which indicates a period of heightened operational efficiency or structural adjustment in current assets.

AI Ask an analyst for more


Turnover Ratios


Average No. Days


Inventory Turnover

Danaher Corp., inventory turnover calculation (quarterly data)

Microsoft Excel
Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Cost of sales 2,360 2,872 2,530 2,413 2,230 2,648 2,397 2,315 2,309 2,626 2,349 2,594 2,287 3,430 3,079 3,030 2,983
Inventories 2,608 2,489 2,674 2,689 2,532 2,330 2,678 2,671 2,645 2,594 3,024 3,183 3,383 3,110 3,236 3,257 3,072
Short-term Activity Ratio
Inventory turnover1 3.90 4.04 3.67 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 3.68 3.65 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96
Amgen Inc. 1.93 1.92 1.88 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48
Bristol-Myers Squibb Co. 5.20 5.18 5.31 5.18 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55
Eli Lilly & Co. 0.85 0.80 0.83 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93
Gilead Sciences Inc. 3.51 3.47 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50
Johnson & Johnson 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Merck & Co. Inc. 2.46 2.27 2.25 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74
Pfizer Inc. 1.51 1.46 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67
Regeneron Pharmaceuticals Inc. 0.74 0.66 0.64 0.64 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27
Thermo Fisher Scientific Inc. 4.85 4.47 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87
Vertex Pharmaceuticals Inc. 0.98 0.99 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83

Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q1 2026 Calculation
Inventory turnover = (Cost of salesQ1 2026 + Cost of salesQ4 2025 + Cost of salesQ3 2025 + Cost of salesQ2 2025) ÷ Inventories
= (2,360 + 2,872 + 2,530 + 2,413) ÷ 2,608 = 3.90

2 Click competitor name to see calculations.


The analysis of inventory activity from April 2022 through March 2026 reveals a pattern of operational stability characterized by cyclical efficiency peaks and a strategic reduction in overall inventory holdings.

Inventory Turnover Trends
The inventory turnover ratio exhibits a consistent cyclical pattern, typically peaking in the fourth quarter of each fiscal year. Significant peaks were recorded in December 2022 (4.03), December 2023 (3.80), December 2024 (4.15), and December 2025 (4.04). Conversely, troughs frequently occur in the first and second quarters, with a notable low of 3.50 in March 2023. This recurrence suggests a seasonal acceleration in inventory movement or a systematic year-end effort to optimize stock levels.
Inventory Volume Management
A gradual downward trend in absolute inventory levels is observed between early 2022 and late 2024. Inventory holdings peaked at 3,383 million USD in March 2023 before declining to a minimum of 2,330 million USD by December 2024. This reduction indicates a transition toward a leaner inventory model, which likely contributed to the higher turnover ratios observed in the latter half of the period.
Cost of Sales Correlation
Cost of sales experienced a period of volatility, peaking at 3,430 million USD in December 2022 before stabilizing within a range of 2,230 million USD to 2,648 million USD for much of 2023 and 2024. The fact that the inventory turnover ratio remained resilient or increased during periods of lower cost of sales suggests that the efficiency gains were driven by the proactive reduction of inventory assets rather than solely by increases in sales volume.

AI Ask an analyst for more


Receivables Turnover

Danaher Corp., receivables turnover calculation (quarterly data)

Microsoft Excel
Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Sales 5,951 6,838 6,053 5,936 5,741 6,538 5,798 5,743 5,796 6,405 5,624 5,912 5,949 8,369 7,663 7,751 7,688
Trade accounts receivable, less allowance for doubtful accounts 3,819 3,913 3,755 3,564 3,506 3,537 3,507 3,298 3,379 3,922 4,201 4,199 4,313 4,918 4,409 4,527 4,407
Short-term Activity Ratio
Receivables turnover1 6.49 6.28 6.46 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.86 4.67 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29
Amgen Inc. 3.67 4.06 3.85 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81
Eli Lilly & Co. 3.92 3.67 3.69 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64
Gilead Sciences Inc. 5.89 5.60 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18
Johnson & Johnson 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Merck & Co. Inc. 5.52 5.30 5.37 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49
Pfizer Inc. 5.27 4.40 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99
Regeneron Pharmaceuticals Inc. 2.60 2.50 2.51 2.53 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41
Thermo Fisher Scientific Inc. 5.01 4.91 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21
Vertex Pharmaceuticals Inc. 5.85 6.02 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15

Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q1 2026 Calculation
Receivables turnover = (SalesQ1 2026 + SalesQ4 2025 + SalesQ3 2025 + SalesQ2 2025) ÷ Trade accounts receivable, less allowance for doubtful accounts
= (5,951 + 6,838 + 6,053 + 5,936) ÷ 3,819 = 6.49

2 Click competitor name to see calculations.


Analysis of short-term operating activity reveals a period of adjustment in revenue volumes and receivables management from early 2022 through early 2026. A notable transition occurred between late 2022 and early 2023, characterized by a contraction in quarterly sales and a corresponding reduction in the trade accounts receivable balance.

Sales and Receivables Correlation
Sales peaked in December 2022 at 8,369 million USD, coinciding with the highest receivables balance of 4,918 million USD. Subsequently, both metrics declined, with receivables reaching a period low of 3,298 million USD in June 2024. This indicates a synchronized adjustment where the scale of credit extended to customers shifted in line with overall revenue changes, preventing a significant buildup of uncollected funds during the sales downturn.
Receivables Turnover Trends
The receivables turnover ratio demonstrates relative stability, fluctuating within a range of 6.09 to 7.15. A recurring cyclical pattern is observed where the ratio typically declines toward the end of the calendar year before recovering in the first quarter. For example, the ratio reached a low of 6.09 in December 2023 and rebounded sharply to 7.02 by March 2024. A similar trend is noted between December 2025 (6.28) and March 2026 (6.49).
Operational Efficiency Analysis
Efficiency in converting receivables into cash remained consistent despite fluctuations in sales volume. The peak turnover ratio of 7.15 in June 2024 suggests an optimization of collection processes or a shift in credit terms during that period. While the ratio experienced a gradual decline throughout 2025, ending at 6.28 in December, the overall trend suggests a disciplined approach to managing the credit cycle across the observed period.

AI Ask an analyst for more


Payables Turnover

Danaher Corp., payables turnover calculation (quarterly data)

Microsoft Excel
Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Cost of sales 2,360 2,872 2,530 2,413 2,230 2,648 2,397 2,315 2,309 2,626 2,349 2,594 2,287 3,430 3,079 3,030 2,983
Trade accounts payable 1,790 1,844 1,698 1,725 1,722 1,753 1,596 1,645 1,679 1,766 1,894 1,956 2,081 2,296 2,191 2,419 2,357
Short-term Activity Ratio
Payables turnover1 5.68 5.45 5.78 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. 5.09 4.29 4.12 5.25 6.74 5.99 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65
Bristol-Myers Squibb Co. 3.38 3.90 3.42 2.61 3.52 3.88 3.43 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25
Eli Lilly & Co. 2.47 2.05 2.37 2.27 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24
Gilead Sciences Inc. 8.72 7.66 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43
Johnson & Johnson 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Merck & Co. Inc. 3.72 3.53 3.82 3.98 3.72 4.26 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25
Pfizer Inc. 3.07 3.32 3.44 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66
Regeneron Pharmaceuticals Inc. 2.24 2.24 2.30 2.83 2.84 2.50 3.87 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39
Thermo Fisher Scientific Inc. 7.27 8.23 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96
Vertex Pharmaceuticals Inc. 3.58 3.83 3.59 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52

Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q1 2026 Calculation
Payables turnover = (Cost of salesQ1 2026 + Cost of salesQ4 2025 + Cost of salesQ3 2025 + Cost of salesQ2 2025) ÷ Trade accounts payable
= (2,360 + 2,872 + 2,530 + 2,413) ÷ 1,790 = 5.68

2 Click competitor name to see calculations.


An analysis of short-term operating activity reveals a strategic contraction in trade liabilities accompanied by an overall increase in the efficiency of payables liquidation over the observed period.

Trade Accounts Payable Trends
A sustained downward trend is observed in trade accounts payable, which declined from 2,357 million USD in April 2022 to 1,790 million USD by March 2026. This represents a significant reduction in the company's outstanding obligations to suppliers, with a particularly sharp decline occurring between December 2022 and June 2024.
Payables Turnover Ratio Evolution
The payables turnover ratio demonstrated a general upward trajectory, moving from a low of 5.00 in July 2022 to a peak of 6.04 in September 2024. This increase indicates that the company began settling its supplier invoices more frequently. In the subsequent period from December 2024 to March 2026, the ratio stabilized, fluctuating within a narrower band between 5.45 and 5.78.
Cost of Sales Volatility
Cost of sales exhibited periodic fluctuations, peaking at 3,430 million USD in December 2022 and reaching a minimum of 2,230 million USD in March 2025. The turnover ratio did not mirror these fluctuations directly, suggesting that the payment cycle is managed independently of short-term variances in cost of sales.

The inverse relationship between the declining balance of trade accounts payable and the increasing payables turnover ratio suggests a shift toward a more accelerated payment cycle. This pattern indicates a reduction in the average time taken to pay suppliers, which may reflect a change in credit terms or a deliberate corporate strategy to reduce short-term liabilities.

AI Ask an analyst for more


Working Capital Turnover

Danaher Corp., working capital turnover calculation (quarterly data)

Microsoft Excel
Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Current assets 13,935 12,756 9,606 10,999 9,525 9,497 10,060 9,609 14,372 13,937 21,205 17,461 16,532 15,883 14,250 13,229 12,670
Less: Current liabilities 7,460 6,807 6,324 6,792 6,645 6,798 7,339 6,701 7,778 8,274 9,367 8,404 8,730 8,389 8,002 7,556 7,547
Working capital 6,475 5,949 3,282 4,207 2,880 2,699 2,721 2,908 6,594 5,663 11,838 9,057 7,802 7,494 6,248 5,673 5,123
 
Sales 5,951 6,838 6,053 5,936 5,741 6,538 5,798 5,743 5,796 6,405 5,624 5,912 5,949 8,369 7,663 7,751 7,688
Short-term Activity Ratio
Working capital turnover1 3.83 4.13 7.39 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc. 9.85 5.66 5.35 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34
Bristol-Myers Squibb Co. 5.84 7.83 6.20 8.09 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24
Eli Lilly & Co. 3.97 3.19 2.71 4.92 4.38 10.32 6.06 12.62 5.45 31.79 12.21 5.77 31.84 14.71 19.45 8.19
Gilead Sciences Inc. 4.43 5.12 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68
Johnson & Johnson 66.14 62.88 24.63 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57
Merck & Co. Inc. 4.28 3.39 5.77 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09
Pfizer Inc. 10.58 6.08 10.68 6.64 8.64 5,036.00 29.17 1.62 2.03 6.89 11.00 3.83 5.05 6.10
Regeneron Pharmaceuticals Inc. 1.14 1.05 1.05 1.08 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46
Thermo Fisher Scientific Inc. 3.30 5.90 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13
Vertex Pharmaceuticals Inc. 1.64 1.92 1.82 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97

Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q1 2026 Calculation
Working capital turnover = (SalesQ1 2026 + SalesQ4 2025 + SalesQ3 2025 + SalesQ2 2025) ÷ Working capital
= (5,951 + 6,838 + 6,053 + 5,936) ÷ 6,475 = 3.83

2 Click competitor name to see calculations.


The analysis of working capital turnover reveals three distinct phases in operational efficiency: a period of declining utilization, a phase of aggressive working capital optimization, and a subsequent return to moderate turnover levels.

Efficiency Erosion (April 2022 – September 2023)
A consistent downward trend in working capital turnover is observed, falling from 5.91 to a low of 2.18. This decline was driven by a substantial expansion in working capital, which grew from 5,123 million USD to a peak of 11,838 million USD, while sales remained relatively stagnant or decreased during the same interval. This divergence indicates an accumulation of current assets or an increase in current liabilities that did not translate into proportional revenue growth.
Operational Optimization (December 2023 – December 2024)
A sharp reversal in the turnover trend occurred starting in December 2023, coinciding with a significant reduction in working capital. The turnover ratio surged from 2.18 to a peak of 8.85 by September 2024. This acceleration was primarily the result of working capital being reduced to its lowest observed levels, reaching approximately 2,699 million USD by December 2024. During this period, the company achieved its highest levels of asset productivity relative to its short-term capital investment.
Normalization and Volatility (January 2025 – March 2026)
The final phase is characterized by increased volatility and a gradual return to previous turnover norms. Working capital began to rise again, increasing from 2,880 million USD in March 2025 to 6,475 million USD by March 2026. Consequently, the turnover ratio retracted from its peak, ending the period at 3.83. This suggests a strategic reallocation of liquidity or a shift in the operating cycle that moved the company away from the lean working capital levels maintained in 2024.

AI Ask an analyst for more


Average Inventory Processing Period

Danaher Corp., average inventory processing period calculation (quarterly data)

Microsoft Excel
Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data
Inventory turnover 3.90 4.04 3.67 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87
Short-term Activity Ratio (no. days)
Average inventory processing period1 94 90 99 101 96 88 101 102 98 96 104 102 104 91 96 98 94
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 99 100 107 98 90 89 75 75 73 77 85 81 75 66 73 74
Amgen Inc. 189 190 194 195 199 209 257 321 411 259 265 279 281 272 260 247
Bristol-Myers Squibb Co. 70 70 69 70 69 67 102 98 99 91 84 83 93 84 76 79 80
Eli Lilly & Co. 428 454 441 435 379 329 349 316 312 298 261 267 268 237 196 204 189
Gilead Sciences Inc. 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Johnson & Johnson 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Merck & Co. Inc. 148 160 162 150 147 149 153 151 144 139 137 134 124 118 119 133
Pfizer Inc. 242 251 239 229 222 219 178 170 149 138 158 119 95 101 100 99
Regeneron Pharmaceuticals Inc. 491 556 571 570 582 572 573 562 553 519 508 532 549 562 440 379 287
Thermo Fisher Scientific Inc. 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Vertex Pharmaceuticals Inc. 373 369 345 320 287 267 238 222 214 213 192 177 156 136 135 129

Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q1 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 3.90 = 94

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a cyclical pattern in inventory management, characterized by periodic fluctuations in both turnover rates and processing durations. Overall, the metrics indicate a stable operational capacity with specific peaks in efficiency recurring toward the end of the calendar years.

Inventory Turnover Trends
The inventory turnover ratio fluctuated between a minimum of 3.50 in March 2023 and a maximum of 4.15 in December 2024. A consistent pattern is observed where turnover rates accelerate during the fourth quarter of each year, suggesting increased sales velocity or strategic inventory reductions prior to year-end reporting.
Average Inventory Processing Period Analysis
The duration required to process inventory generally remained within a range of 88 to 104 days. A period of decreased efficiency occurred during the first three quarters of 2023, with the processing period reaching a peak of 104 days in March and September. Significant improvements in processing speed were recorded in December 2024 and December 2025, where the period declined to 88 and 90 days, respectively.
Operational Efficiency Correlation
A precise inverse correlation is maintained between the turnover ratio and the average processing period. The shift from a 104-day processing cycle in late 2023 to an 88-day cycle by December 2024 reflects a notable increase in throughput efficiency. The subsequent rise to 94 days by March 2026 suggests a return to baseline operational levels following the year-end efficiency spikes.

AI Ask an analyst for more


Average Receivable Collection Period

Danaher Corp., average receivable collection period calculation (quarterly data)

Microsoft Excel
Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data
Receivables turnover 6.49 6.28 6.46 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87
Short-term Activity Ratio (no. days)
Average receivable collection period1 56 58 56 54 54 54 54 51 52 60 59 55 53 57 51 54 53
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 75 78 79 79 71 75 78 80 75 76 75 74 71 68 72 69
Amgen Inc. 99 90 95 91 77 86 86 88 99 88 84 84 82 79 79 76
Eli Lilly & Co. 93 99 99 97 90 89 92 103 80 97 93 93 99 88 84 80 79
Gilead Sciences Inc. 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Johnson & Johnson 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Merck & Co. Inc. 66 69 68 62 58 66 68 68 63 64 69 66 58 59 62 66
Pfizer Inc. 69 83 69 69 66 87 74 72 69 58 48 48 40 59 55 52
Regeneron Pharmaceuticals Inc. 140 146 146 144 144 160 161 155 146 158 156 148 151 160 148 132 107
Thermo Fisher Scientific Inc. 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Vertex Pharmaceuticals Inc. 62 61 61 59 53 60 58 64 58 58 60 61 59 58 58 59

Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q1 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.49 = 56

2 Click competitor name to see calculations.


The average receivable collection period exhibits moderate volatility over the analyzed period, fluctuating within a range of 51 to 60 days. A consistent inverse correlation is observed between the receivables turnover ratio and the collection period, where declines in turnover efficiency correspond directly with an increase in the number of days required to collect outstanding receivables.

Trend Analysis 2022-2023
During the initial phase of the analysis, the collection period remained relatively stable between 51 and 54 days. However, a period of deterioration in collection efficiency began in late 2022, with the collection period rising to 57 days by December 31, 2022. Despite a brief recovery to 53 days in March 2023, a steady upward trend ensued throughout the remainder of the year, culminating in a peak of 60 days by December 31, 2023.
Operational Efficiency Peak
A significant improvement in liquidity management occurred in the first half of 2024. The collection period dropped sharply from 60 days in December 2023 to 52 days in March 2024, reaching a period low of 51 days by June 28, 2024. This efficiency peak aligned with the highest recorded receivables turnover ratio of 7.15, indicating an optimal acceleration of cash inflows during this window.
Stabilization and Recent Performance
From September 2024 through March 2026, the collection period entered a phase of relative stabilization, primarily oscillating between 54 and 58 days. A slight upward trend is observable toward the end of 2025, where the collection period reached 58 days in December before settling at 56 days by March 27, 2026. This suggests a marginal easing of collection urgency compared to the efficiency peaks of mid-2024, though it remains more favorable than the lows observed in late 2023.

AI Ask an analyst for more


Operating Cycle

Danaher Corp., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data
Average inventory processing period 94 90 99 101 96 88 101 102 98 96 104 102 104 91 96 98 94
Average receivable collection period 56 58 56 54 54 54 54 51 52 60 59 55 53 57 51 54 53
Short-term Activity Ratio
Operating cycle1 150 148 155 155 150 142 155 153 150 156 163 157 157 148 147 152 147
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 174 178 186 177 161 164 153 155 148 153 160 155 146 134 145 143
Amgen Inc. 288 280 289 286 276 295 343 409 510 347 349 363 363 351 339 323
Eli Lilly & Co. 521 553 540 532 469 418 441 419 392 395 354 360 367 325 280 284 268
Gilead Sciences Inc. 166 170 169 159 156 160 172 164 163 169 163 159 162 137 136 132
Johnson & Johnson 239 238 246 240 228 226 236 233 222 218 211 232 220 209 196 198 192
Merck & Co. Inc. 214 229 230 212 205 215 221 219 207 203 206 200 182 177 181 199
Pfizer Inc. 311 334 308 298 288 306 252 242 218 196 206 167 135 160 155 151
Regeneron Pharmaceuticals Inc. 631 702 717 714 726 732 734 717 699 677 664 680 700 722 588 511 394
Thermo Fisher Scientific Inc. 148 156 153 148 142 150 144 142 142 146 146 145 145 148 157 164
Vertex Pharmaceuticals Inc. 435 430 406 379 340 327 296 286 272 271 252 238 215 194 193 188

Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q1 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 94 + 56 = 150

2 Click competitor name to see calculations.


The operating cycle exhibits a period of volatility between April 2022 and March 2026, characterized by fluctuations that primarily correlate with changes in inventory management. The overall duration ranged from a minimum of 142 days to a maximum of 163 days, indicating a variable timeline for converting current assets into cash.

Average Inventory Processing Period
Inventory turnover efficiency showed notable variance, starting at 94 days in April 2022 and peaking at 104 days during March and September 2023. A significant reduction to a low of 88 days occurred in December 2024, before the period stabilized around 94 days by March 2026. These shifts suggest periodic adjustments in inventory levels or fluctuations in demand during the analyzed timeframe.
Average Receivable Collection Period
The collection of receivables remained relatively stable compared to inventory processing. The period hovered between 51 and 60 days. A peak of 60 days was reached in December 2023, followed by a prompt improvement to 51 days by June 2024. For the remainder of the period through March 2026, the collection cycle remained consistent, fluctuating narrowly between 54 and 58 days.
Operating Cycle
The total operating cycle mirrored the trends of the inventory processing period, as that metric represented the larger component of the cycle. The cycle peaked at 163 days in September 2023, coinciding with a peak in inventory days. The shortest cycle was recorded in December 2024 at 142 days, driven by the lowest recorded inventory processing time. The cycle concluded at 150 days in March 2026, returning to a level near the baseline established at the start of the analysis period.

The analysis indicates that the operating cycle is more sensitive to inventory management than to receivable collection. While receivable periods remained largely controlled, the variability in the inventory processing period acted as the primary driver for the expansion and contraction of the overall operating cycle.

AI Ask an analyst for more


Average Payables Payment Period

Danaher Corp., average payables payment period calculation (quarterly data)

Microsoft Excel
Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data
Payables turnover 5.68 5.45 5.78 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04
Short-term Activity Ratio (no. days)
Average payables payment period1 64 67 63 65 66 66 60 63 62 65 65 63 64 67 65 73 72
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. 72 85 89 70 54 61 73 60 69 70 64 73 90 69 72 78
Bristol-Myers Squibb Co. 108 94 107 140 104 94 106 120 117 111 97 108 114 109 96 107 112
Eli Lilly & Co. 148 178 154 161 140 140 135 142 127 134 130 138 119 106 86 87 70
Gilead Sciences Inc. 42 48 34 43 49 49 29 34 31 37 40 41 58 33 31 32
Johnson & Johnson 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Merck & Co. Inc. 98 103 95 92 98 86 83 81 89 80 80 84 89 71 75 86
Pfizer Inc. 119 110 106 110 115 99 79 87 98 72 93 76 72 66 59 55
Regeneron Pharmaceuticals Inc. 163 163 158 129 129 146 94 110 137 122 106 116 136 138 98 91 68
Thermo Fisher Scientific Inc. 50 44 43 44 45 38 37 37 41 35 34 39 48 37 41 46
Vertex Pharmaceuticals Inc. 102 95 102 105 98 98 85 96 106 117 115 107 103 44 73 66

Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q1 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 5.68 = 64

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a period of optimization in accounts payable management, characterized by an initial tightening of payment cycles followed by a return to a stable baseline. Between April 2022 and March 2026, the company exhibited a consistent ability to manage its obligations to suppliers with low volatility.

Payables Turnover
The payables turnover ratio demonstrated a gradual upward trend for the majority of the period. Starting at 5.04 in April 2022, the ratio reached a peak of 6.04 by September 27, 2024. This increase indicates a higher frequency of supplier payments and an acceleration in the turnover of accounts payable. Following this peak, the ratio experienced a moderate correction, fluctuating between 5.45 and 5.88 through March 2026, suggesting a stabilization of payment frequency.
Average Payables Payment Period
The average payment period shows a corresponding inverse relationship with the turnover ratio. The period began with a peak of 73 days in July 2022, followed by a steady contraction. The shortest payment cycle was recorded on September 27, 2024, at 60 days, marking the point of maximum payment efficiency. Subsequently, the payment period expanded slightly, fluctuating between 63 and 67 days during the final year of the analyzed period. This suggests a strategic shift from an accelerated payment phase back toward a more standard operational cycle.
Operational Correlation and Stability
The synchronization between the increasing turnover ratio and the decreasing payment period until late 2024 indicates a deliberate effort to reduce the time held for payables. The subsequent stabilization—where the payment period settled around 64 to 67 days and the turnover ratio hovered around 5.6—points to a sustainable equilibrium in working capital management. The narrow range of these fluctuations suggests a disciplined approach to liquidity and a consistent relationship with the vendor base.

AI Ask an analyst for more


Cash Conversion Cycle

Danaher Corp., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data
Average inventory processing period 94 90 99 101 96 88 101 102 98 96 104 102 104 91 96 98 94
Average receivable collection period 56 58 56 54 54 54 54 51 52 60 59 55 53 57 51 54 53
Average payables payment period 64 67 63 65 66 66 60 63 62 65 65 63 64 67 65 73 72
Short-term Activity Ratio
Cash conversion cycle1 86 81 92 90 84 76 95 90 88 91 98 94 93 81 82 79 75
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc. 216 195 200 216 222 234 270 349 441 277 285 290 273 282 267 245
Eli Lilly & Co. 373 375 386 371 329 278 306 277 265 261 224 222 248 219 194 197 198
Gilead Sciences Inc. 124 122 135 116 107 111 143 130 132 132 123 118 104 104 105 100
Johnson & Johnson 116 93 127 121 105 89 116 112 109 86 100 99 100 72 78 82 80
Merck & Co. Inc. 116 126 135 120 107 129 138 138 118 123 126 116 93 106 106 113
Pfizer Inc. 192 224 202 188 173 207 173 155 120 124 113 91 63 94 96 96
Regeneron Pharmaceuticals Inc. 468 539 559 585 597 586 640 607 562 555 558 564 564 584 490 420 326
Thermo Fisher Scientific Inc. 98 112 110 104 97 112 107 105 101 111 112 106 97 111 116 118
Vertex Pharmaceuticals Inc. 333 335 304 274 242 229 211 190 166 154 137 131 112 150 120 122

Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q1 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 94 + 5664 = 86

2 Click competitor name to see calculations.


The cash conversion cycle exhibits a fluctuating trend over the analyzed period, characterized by a general increase through 2023, followed by a period of volatility and partial correction through early 2026. The cycle reached a peak of 98 days in September 2023 before declining to a low of 76 days by December 2024, ultimately settling at 86 days by March 2026.

Average Inventory Processing Period
Inventory management represents the most volatile component of the operating cycle. The period fluctuated between a minimum of 88 days in December 2024 and a maximum of 104 days in March and September 2023. A pattern of expansion is observed during the first half of the analyzed timeline, with a subsequent trend toward shorter processing times in late 2024 and late 2025, suggesting periodic optimizations or seasonal inventory drawdowns.
Average Receivable Collection Period
The collection of receivables remained relatively stable, maintaining a narrow range between 51 and 60 days. A slight increase in the collection period was observed during the second half of 2023, peaking at 60 days in December 2023. However, the period stabilized between 52 and 56 days from March 2024 through March 2026, indicating consistent credit management and collection efficiency.
Average Payables Payment Period
Payment terms for payables showed a gradual downward trend from early 2022, where the period peaked at 73 days in July 2022. A low of 60 days was recorded in September 2024. Since then, the period has stabilized between 63 and 67 days. This reduction in the payment period suggests a shift toward faster supplier payments or a change in the composition of supplier credit terms.
Cash Conversion Cycle Synthesis
The overall cash conversion cycle is primarily driven by movements in the inventory processing period. The spike in the cycle to 98 days in September 2023 was directly correlated with peak inventory durations (104 days) and a rise in receivable collection times (59 days). Conversely, the most significant improvement in liquidity efficiency occurred in December 2024, where the cycle dropped to 76 days due to a simultaneous decrease in inventory processing (88 days) and an increase in the payables payment period (66 days). The data indicates that while receivable collections are stable, the company's short-term liquidity is highly sensitive to inventory turnover rates.

AI Ask an analyst for more